NCT04835402View on ClinicalTrials.gov

Electroporation Potentiated Immunotherapy in Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

March 7, 2022

Study Completion Date

December 31, 2025

Conditions
Pancreas Cancer, Metastatic
Interventions
DRUG

Pembrolizumab

400mg every 6 weeks

DEVICE

Irreversible electroporation

Percutaneous ablation of one liver metastasis

Trial Locations (1)

DK-9000

Department of Oncology, Aalborg

All Listed Sponsors
collaborator

Odense University Hospital

OTHER

collaborator

Aalborg University

OTHER

collaborator

Danish Cancer Society

OTHER

lead

Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery

OTHER